These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35358437)

  • 1. Melflufen in multiple myeloma: the conclusion matters.
    Hadidi SA
    Lancet Haematol; 2022 Apr; 9(4):e244. PubMed ID: 35358437
    [No Abstract]   [Full Text] [Related]  

  • 2. Melflufen in multiple myeloma: the conclusion matters - Authors' reply.
    Schjesvold FH; Bakker NA; Sonneveld P
    Lancet Haematol; 2022 Apr; 9(4):e244-e245. PubMed ID: 35358436
    [No Abstract]   [Full Text] [Related]  

  • 3. Melflufen for relapsed and refractory multiple myeloma.
    Oriol A; Larocca A; Leleu X; Hajek R; Hassoun H; Rodríguez-Otero P; Paner A; Schjesvold FH; Gullbo J; Richardson PG
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1069-1078. PubMed ID: 32924646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo activity of melflufen (J1)in lymphoma.
    Delforoush M; Strese S; Wickström M; Larsson R; Enblad G; Gullbo J
    BMC Cancer; 2016 Apr; 16():263. PubMed ID: 27044263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
    Morabito F; Tripepi G; Martino EA; Vigna E; Mendicino F; Morabito L; Todoerti K; Al-Janazreh H; D'Arrigo G; Canale FA; Cutrona G; Neri A; Martino M; Gentile M
    Drug Des Devel Ther; 2021; 15():2969-2978. PubMed ID: 34262262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.
    Ray A; Ravillah D; Das DS; Song Y; Nordström E; Gullbo J; Richardson PG; Chauhan D; Anderson KC
    Br J Haematol; 2016 Aug; 174(3):397-409. PubMed ID: 27098276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
    Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
    Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melflufen: A Next-Generation Nitrogen Mustard.
    Holstein SA; Hillengass J; McCarthy PL
    J Clin Oncol; 2021 Mar; 39(7):836-839. PubMed ID: 33439689
    [No Abstract]   [Full Text] [Related]  

  • 9. Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen.
    Gebraad A; Ohlsbom R; Miettinen JJ; Emeh P; Pakarinen TK; Manninen M; Eskelinen A; Kuismanen K; Slipicevic A; Lehmann F; Nupponen NN; Heckman CA; Miettinen S
    Cells; 2022 May; 11(9):. PubMed ID: 35563880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melflufen for multiple myeloma: a promise unfulfilled?
    Kapoor P; Gonsalves WI
    Lancet Haematol; 2022 Feb; 9(2):e82-e84. PubMed ID: 35032433
    [No Abstract]   [Full Text] [Related]  

  • 11. OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
    Schjesvold F; Robak P; Pour L; Aschan J; Sonneveld P
    Future Oncol; 2020 Apr; 16(11):631-641. PubMed ID: 32141766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma.
    Huledal G; Ruiz-Garcia A; Kawakatsu S; Wang X; Sjöberg P; Gullbo J; Pekar D; Norin S; Jerling M
    J Clin Pharmacol; 2024 Feb; 64(2):240-252. PubMed ID: 37752623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melflufen for the treatment of multiple myeloma.
    Ocio EM; Nadeem O; Schjesvold F; Gay F; Touzeau C; Dimopoulos MA; Richardson PG; Mateos MV
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):371-382. PubMed ID: 35723075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma.
    Pour L; Micheva I; Usenko G; Mikala G; Masszi T; Simeonova K; Thuresson M; Huledal G; Norin S; Bakker NA; Minarik J
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e267-e275.e2. PubMed ID: 38490927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melflufen, a peptide-conjugated alkylator, is an efficient anti-neo-plastic drug in breast cancer cell lines.
    Schepsky A; Traustadottir GA; Joelsson JP; Ingthorsson S; Kricker J; Bergthorsson JT; Asbjarnarson A; Gudjonsson T; Nupponen N; Slipicevic A; Lehmann F; Gudjonsson T
    Cancer Med; 2020 Sep; 9(18):6726-6738. PubMed ID: 32717133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo.
    Strese S; Wickström M; Fuchs PF; Fryknäs M; Gerwins P; Dale T; Larsson R; Gullbo J
    Biochem Pharmacol; 2013 Oct; 86(7):888-95. PubMed ID: 23933387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.
    Strese S; Hassan SB; Velander E; Haglund C; Höglund M; Larsson R; Gullbo J
    Oncotarget; 2017 Jan; 8(4):6341-6352. PubMed ID: 27974676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.
    Berglund Å; Ullén A; Lisyanskaya A; Orlov S; Hagberg H; Tholander B; Lewensohn R; Nygren P; Spira J; Harmenberg J; Jerling M; Alvfors C; Ringbom M; Nordström E; Söderlind K; Gullbo J
    Invest New Drugs; 2015 Dec; 33(6):1232-41. PubMed ID: 26553306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma.
    Banerjee R; Midha S; Kelkar AH; Goodman A; Prasad V; Mohyuddin GR
    Br J Haematol; 2022 Mar; 196(5):1274-1277. PubMed ID: 34750805
    [No Abstract]   [Full Text] [Related]  

  • 20. Preclinical activity of melflufen (J1) in ovarian cancer.
    Carlier C; Strese S; Viktorsson K; Velander E; Nygren P; Uustalu M; Juntti T; Lewensohn R; Larsson R; Spira J; De Vlieghere E; Ceelen WP; Gullbo J
    Oncotarget; 2016 Sep; 7(37):59322-59335. PubMed ID: 27528037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.